Completed PHASE3 INTERVENTIONAL NCT00002315

A Comparison of 882C87 Versus Acyclovir in the Treatment of Herpes Zoster in Patients With Weakened Immune Systems

A Double-Blind, Multicenter Study Comparing Oral 882C87 With Oral Acyclovir for Treatment of Localized Herpes Zoster in Immunocompromised Patients

Sponsor: Glaxo Wellcome

Conditions Chickenpox HIV Infections

Interventions Acyclovir Netivudine

Updated 6 times since 2017 Last updated: Jun 23, 2005

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT00002315, this PHASE3 trial focuses on Chickenpox and HIV Infections and remains completed. Sponsored by Glaxo Wellcome, it has been updated 6 times since 2026, reflecting limited change activity. This study is part of the global effort to build evidence for infectious disease interventions.

Status Flow

Change History

6 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE3
Sep 2024 — Sep 2025 [monthly]

Completed PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE3
Jan 2021 — Jul 2024 [monthly]

Completed PHASE3
Jun 2018 — Jan 2021 [monthly]

Completed PHASE3

▶ Show 1 earlier version

Jan 2017 — Jun 2018 [monthly]

Completed PHASE3

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Glaxo Wellcome

Data source: NIH AIDS Clinical Trials Information Service

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Albuquerque, United States , Birmingham, United States , Dallas, United States , Dubuque, United States , Eugene, United States , High Point, United States , Houston, United States , Los Angeles, United States , Milwaukee, United States , Nashville, United States and 13 more locations